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Abstract 
Introduction: Correlations between subjective and objective measures of constipation have seldom 
been demonstrated. This could be due to multiple confounding factors in clinical studies and the 
broad span of symptoms represented in questionnaires used to assess constipation. We developed a 
new method for categorizing gastrointestinal (GI) symptoms into relevant symptom groups, and 
used this in a controlled experimental study aimed to investigate whether GI transit times and 
colonic volumes were correlated to self-reported GI symptoms. 
Methods: Twenty-five healthy male participants were enrolled in a randomized, double-blinded, 
placebo-controlled, five-day crossover study with the treatments oxycodone and placebo. Objective 
measures of GI transit times and colonic volumes were obtained by the means of the 3D-Transit 
System and magnetic resonance colonography, whereas subjective GI symptoms were measures via 
three validated questionnaires. The symptoms were then categorized into five groups; “abdominal 
symptoms”, “defecation difficulties”, “incomplete bowel evacuation”, “reduced bowel movement 
frequency”, and “stool symptoms”. Spearman’s rank order correlation was used to determine 
correlations between the five groups of symptoms and the objective measures. 
Results: No correlations between the GI symptoms and transit times or colonic volumes were found 
(all P > 0.05).  
Discussion: GI transit times and colonic volumes were not correlated to self-reported GI symptoms 
even in a controlled experimental study and when symptoms were categorized into relevant 
symptom groups. Thus, both subjective and objective measures must be considered relevant when 
assessing constipation in clinical and research settings, ensuring that both physiological aspects as 
well as the severity and impact of symptoms experienced by patients can be assessed. 
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Introduction 
Constipation is a common condition that affects people of all ages, with a prevalence estimation of 
up to 27 percent in the population of Western countries (Pare, Ferrazzi, Thompson, Irvine, & Rance, 
2001; Peppas, Alexiou, Mourtzoukou, & Falagas, 2008). The causes of constipation are multiple, 
ranging from physical inactivity, pharmacological-induced motility dysfunction (e.g. induced by 
opioids and anticholinergics), to advanced cancer illness (Hayat, Dugum, & Garg, 2017). To handle 
constipation in the clinic, and to investigate physiological mechanisms of constipation in research 
studies, valid subjective and objective methods are of great importance. Subjective questionnaires 
such as the Bowel Function Index (BFI) and Cleveland Clinical Constipation scores are commonly 
used to evaluate the severity and impact of gastrointestinal (GI) symptoms experienced by patients 
with constipation, and to guide clinicians in diagnostics and choice of treatment (Argoff et al., 
2015). The purpose of objective measures is to gain insights into underlying physiological aspects 
of GI function, and to assess the efficacy of pharmacological treatment options (Matias Nilsson et 
al., 2016; Olesen & Drewes, 2011). Usually, a combination of measures are applied. However, if 
subjective and objective measures of constipation are directly correlated, it may be beneficial 
utilizing merely the subjective measures as this would reduce clinical trial costs, ease participant 
discomforts, and increase compliance (Grønlund et al., 2018; Stotzer, Fjälling, Grétarsdóttir, & 
Abrahamsson, 1999). Nevertheless, previous clinical studies regarding GI function in patients with 
constipation have not found any correlations between subjective and objective measures (Chaussade 
et al., 1989; Cowlam et al., 2008; Knudsen, Krogh, Østergaard, & Borghammer, 2017). An 
explanation for this may lie within the design of clinical studies in which confounding factors, e.g. 
multiple GI diseases, psychological factors, and concomitant drug use to a great extent can 
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influence the results. A better alternative may be to investigate such correlations in a more 
controlled setting, e.g. in opioid-induced constipation in healthy participants. Opioids cause GI 
dysmotility through multiple mechanism; decreased neuronal excitability of the enteric nervous 
system, decreased gut secretion and gut sphincter dysfunction (Brock et al., 2012). Thus, Nilsson et 
al., and Poulsen et al., recently conducted a crossover study employing a model of oxycodone-
induced constipation to investigate whether self-reported GI symptoms (measured with three 
questionnaires) were correlated to GI transit times (measured with the 3D-Transit system), and 
colonic volumes (measured using magnetic resonance imaging (MRI)) (Matias Nilsson et al., 2016; 
Poulsen et al., 2016).  
However, no correlations between the subjective and objective measures were found here either. 
This could be due to the very broad span of symptoms appearing in the applied questionnaires.  
Thus, it may be beneficial to stratify the GI symptoms assessed in the questionnaires and categorize 
these into relevant symptoms groups, to simplify the correlations and decrease the risk of type 1 
errors. The aim of the current study was to investigate correlations between GI symptoms and GI 
transit time/colonic volume using a new method categorizing symptoms into symptom-and GI 
regions-specific groups approach. We hypothesized that using this approach, significant correlations 
between the subjective and objective measures would be found.  
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Methods 
Data source 
The study from which these data origin was designed as a randomized, double-blinded, placebo-
controlled, crossover trial to assess how opioids affect the GI tract. The North Denmark Region 
Committee on Health Research Ethics (N-20130030) and the Danish Medicines Agency 
(2013070299) approved the study, and it was conducted in accordance with the principles of ICH-
GCP of the European Union. The full trial protocol is registered at www.clinicaltrialsregister.eu 
(EudraCT no. 2013-001540-60). Twenty-five healthy male participants with no current symptoms 
or history of GI disease were recruited. All underwent a screening session in which a physician 
obtained their medical history and performed a physical examination, and the participants gave 
written informed consent. The study consisted of two separate five-day periods, in which the 
participants were randomized using computer generated block-randomization to receive either oral 
prolonged-release oxycodone (OxyContin®, 5 mg twice on day 1, 10 mg twice on day 2-4, and 10 
mg once on day 5) or placebo. Medication was provided by Mundipharma Research Ltd 
(Cambridge, UK). In short, oxycodone treatment induced constipation by the means of significantly 
increased GI symptoms, increased total GI transit time and colonic transit time, and increased 
volume in the cecum/ascending- and transverse colon. Further details on in- and exclusion criteria, 
study design, experimental procedures, and results are found in the previous publications from the 
study (Matias Nilsson et al., 2016; Poulsen et al., 2016). For the current sub-study, merely data 
from the oxycodone treatment period was used in the correlation analyses.  
 
Subjective measures 
To assess GI symptoms, participants filled in the Danish versions of three well-validated 
questionnaires; The BFI (Table 1), the Gastrointestinal Symptom Rating Scale (GSRS) (Table 2), 
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and the Patient Assessment of Constipation Symptoms (PAC-SYM) (Table 3). The BFI and GSRS 
were filled in at day 1 and 5, whilst PAC-SYM was filled in once daily throughout the study period. 
For the present study, data from day 5 of all three questionnaires were used in the correlation 
analyses.  
    The BFI is a 3-item questionnaire to measure constipation. All three items are evaluated by the 
patient on a numeric analogue scale from 0 to 100 where 0 = no problems and 100 = most severe 
problems. The BFI has been validated against bowel movements and laxative use, and assesses the 
severities of three GI symptoms; defecation difficulties, feeling of incomplete evacuation, and 
personal judgement of constipation (Ducrotté & Caussé, 2012; Rentz, Yu, Müller-Lissner, & 
Leyendecker, 2009). The symptoms are rated on a numerical rating scale from 0-10, 0 signifying 
‘not at all’ and 10 signifying ‘very strong’. It is the only scale specially designed for opioid-induced 
constipation (Olesen & Drewes, 2011).  
Table 1. The Bowel Function Index (BFI) items. 
ITEM 
1. Ease of defecation during the last 7 days according to patient assessment 
2. Feeling of incomplete bowel evacuation during the last 7 days according to patient 
assessment 
3. Personal judgment of patient regarding constipation during the last 7 days 
 
 
    The GSRS is a well-validated questionnaire composing of 15 items assigned to five syndromes: 
gastroesophageal reflux, abdominal pain, indigestion, diarrhoea, and constipation. Each question is 
rated on a 7-point Likert scale, where 1 represents absence of symptoms and 7 represents very 
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bothersome symptoms (Kulich et al., 2008; Revicki, Wood, Wiklund, & Crawley, 1998). The 
subjects 
used the Danish version of the GSRS including an appendix of six questions related to dryness of 
the mouth, nausea, anorexia, dysphagia, need to push and squeeze when trying to pass a stool or 
during defecation. 
Table 2. The Gastrointestinal Symptom Rating Scale (GSRS) syndromes and items. 
SYNDROME ITEM  
Gastroesophageal reflux 2.   
3.   
Heartburn  
Acid regurgitation 
Abdominal pain 1.   
4.   
5.   
Abdominal pains 
Sucking sensation in the epigastrium 
Nausea and vomiting 
Indigestion 6.   
7.   
8.   
9.   
Borborygmus  
Abdominal distension 
Eructation 
Increased flatus 
Diarrhea 11.   
12.  
14.  
Increased passage og stools  
Loose stools  
Urgent need for defecation 
Constipation 10.  
13.  
15.  
Decreased passage of stools  
Hard stools  
Feeling of incomplete evacuation 
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    The PAC-SYM has been validated with a high test-retest reliability, and is a 12-item 
questionnaire assigned to three domains: abdominal symptoms, rectal symptoms, and stool 
symptoms (Frank, Kleinman, Farup, Taylor, & Miner, 1999; Slappendel, Simpson, Dubois, & 
Keininger, 2006). Each question is rated on a 5-point Likert scale, where 0 represents absence of 
symptoms and 4 represents very severe symptoms. Responses are scored as 0=absence of symptom, 
1=mild, 2=moderate, 3=severe and 4=very severe. 
Table 3. Patient Assessment of Constipation Symptoms (PAC-SYM) domains and items. 
DOMAIN ITEM 
Abdominal 1. Discomfort in your stomach 
2. Pain in your stomach 
3. Bloating in your stomach 
4. Stomach cramps 
Rectal 5. Painful bowel movements 
6. Rectal burning during or after bowel movement 
7. Rectal bleeding or tearing during or after bowel movement 
Stool 8. Incomplete bowel movements, like you did not finish 
9. Bowel movements that were to hard 
10. Bowel movements that were to small 
11. Straining or squeezing to try to pass a bowel movement 
12. Feeling like you had to pass a bowel movement but could not (“false alarm”) 
 
Symptom categorization 
To categorize symptoms into relevant groups, homogenization of the questionnaires was necessary. 
Thus, the GSRS scale was modified from 1-7 to 0-6 in order to have a “true zero” corresponding the 
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BFI and PAC-SYM. Hereafter, all three questionnaires were converted into 0-100 scales. This 
modification assumed that the level between each number were equal between all questionnaires, 
and that the minimum and maximum levels were equal. Collectively, the questionnaires included 36 
questions, each referring to a specific GI symptom. The number of times the participants reported a 
specific symptom (i.e. a score ≥ 1) were counted, as done in a previous study (Amanzio, Corazzini, 
Vase, & Benedetti, 2009). A symptom was included in the correlation analyses if the following 
three criteria were met: 1) ≥ 15 % of the participants reported the specific symptom on day 5 (Burns 
et al., 1999; Nakamura, Osonoi, & Terauchi, 2010), 2) the number of participants reporting the 
specific symptom increased with ≥ 15 % from day 1 to day 5, and 3) the symptom was related to 
either the small intestine, colon or anal sphincter, as these were the areas of the GI tract assessed 
with the objective measures. This selection resulted in a total of 18 symptoms, which were 
categorized into the following five groups; “abdominal symptoms”, “defecation difficulties”, 
“incomplete bowel evacuation”, “reduced bowel movement frequency”, and “stool symptoms” 
based on their physiological relations (Amanzio, Benedetti, & Vase, 2012; Amanzio et al., 2009). 
The procedure for categorizing the symptoms into groups is illustrated in Figure 1. To obtain a total 
score for each group, mean composite scores were calculated and baseline-corrected, resulting in 
scores for each group in the range of -100 to 100. 
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Figure 1. Categorization of the self-reported GI symptoms. The numbers indicated next to 
questionnaire abbreviations represent the order of the questions in each of the questionnaires. For 
example, the PAC-SYM6 refers to the sixth question in the PAC-SYM questionnaire. BFI: The 
bowel function index, GSRS: The gastrointestinal symptom rating scale, GSRSA: The 
gastrointestinal symptom rating scale appendix question. PAC-SYM: The patient assessment of 
constipation symptoms.  
 
Objective measures 
Gastrointestinal transit time 
On day 1, after administration of the first study medication dose, participants had a standardized 
meal, and the 3D-Transit capsule was swallowed with a glass of water. Participants were instructed 
to carry a detector fitted to the abdomen in an elastic belt, in order to track the 3D-Transit capsule 
throughout the GI tract.   
     The 3D-Transit system is a novel, well-validated, minimally invasive tool for the ambulatory 
evaluation of total and segmental GI transit times (Haase et al., 2014; Kalsi et al., 2018). Technical 
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specifications of the system, and detailed information on data analysis, is described in details 
elsewhere (Haase et al., 2014; Poulsen et al., 2016). In short, total GI - and regional (small intestine 
and colon) transit times were determined manually by a trained researcher using specialized 
software (Motilis Medica SA, Lausanne, Switzerland). Changes in contraction frequencies observed 
on capsule rotation graphs and 2D plots of the anatomical position were used to determine when the 
capsule progressed from the stomach into the duodenum, i.e. gastric emptying (a shift in contraction 
frequency from 3 to 9-12 contractions per minute) and from the ileum to the right colon (from 9-12 
to 3 contractions per minute). The total GI transit time was defined as the time between ingestion 
and expulsion of the capsule. If the capsule had not been expelled by day 5, the time of the last 
confirmed capsule-signal was used as the earliest possible expulsion time. Segmental colonic transit 
times (ascending/cecum, transverse, descending and rectosigmoid) were determined using a custom 
MATLAB (R2015b version 8.6, MathWorks, Inc, Natick, MA, USA) application, allowing the 
researcher to determine the capsule passage from the hepatic flexure, splenic flexure and the 
descending-sigmoid junction (Figure 2A), a method previously validated (Poulsen et al., 2016).  
 
 
Figure 2. Objective measurement methods. (A) 3D-Transit recording of capsule transit through the 
colon. Blue dots indicate capsule progression according, where each hour of recording is written in 
numbers. Colorectal segments are chosen according to landmarks (hepatic flexure, splenic flexure, 
and the end of descending colon) shown by red arrows. (B) MRI of the abdomen. Regions of 
interest surround colonic segments; yellow is ascending colon, red is transverse colon, green is 
descending colon, and blue is rectosigmoid colon. 
 
ACCEPTED MANUSCRIPT
AC
C
EP
TE
D
 M
AN
U
SC
R
IP
T
 
 
Colonic volume 
All MRI scans were acquired using a GE Discovery MR450 1.5 T MRI System (GE Healthcare, 
Milwaukee, Wisconsin, USA). Participants were scanned in a fasting state in the morning of days 1 
and 5 to assess the amount of faces in colon, however, only colonic volume on day 5 (baseline-
corrected) were used for the present correlation analyses. Total and segmental colonic volumes 
were determined using semiautomatic in-house data analysis software, which has previously been 
validated (Sandberg et al., 2015). In short, colonic content was manually outlined on each of the 40 
MRI slices encapsulating the following colonic segments; ascending colon, transverse colon, 
descending colon, and rectosigmoid colon (Figure 2B). Hereafter, the software automatically 
determined the exact boundaries of the colon and calculated the fecal volume of each colonic 
region. Detailed description of the specific settings for the MRI scans and calculations of colonic 
volumes are described elsewhere (M. Nilsson et al., 2015; Sandberg et al., 2015).  
 
Statistics 
Spearman’s rank-order correlations was used to determine correlations between the five side 
symptom groups and the objective measures (total GI - and regional transit times, total and 
segmental colonic volumes). A Spearman’s Rho of ±0.00 to ±0.30 was considered a negligible 
correlation, ±0.30 to ±0.50 a low correlation, ±0.50 to 0.70 a moderate correlation, ±0.70 to ±0.90 a 
high correlation,  and ±0.90 to ±1.00 a very high correlation (Mukaka, 2012). Analyses were carried 
out using SPSS (Version 25.0, IBM Corp., New York, USA), and due to multiple comparisons, P-
values of < 0.01 were considered statistically significant. All data are reported as medians [IQR], 
unless otherwise stated. 
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Results 
All participants filled in the three questionnaires on day 5. Recordings of total GI - and regional 
transit time were obtained in all participants (25 recordings in total), however, it was not possible to 
determine segmental colonic transit times in 2/25 recordings, due to insufficient data quality. MRI 
scans were missed in 6/25 cases because of capsule retention on day 5 (excluding MRI assessment), 
thus 19 measures of total and segmental colonic volumes were available for the present analyses.   
    The median total GI transit time was 43.9 hours [7.1 - 92.6 hours]. The median total colonic 
volume was 881 mL [783 - 979 mL]. Median scores of the five symptom groups are presented in 
Table 4.  
    No correlations between the symptom groups against total GI - or regional transit times and total 
or segmental colonic volumes were found (all P > 0.1; all |r| < 0.4) (Table 4).  
 
Table 4. Correlations between the symptom groups and the objective measures; transit time and 
colonic volume after 5-days of oxycodone treatment in healthy males. Spearman’s correlation 
coefficient (r): ±0.00 to ±0.30; a negligible correlation, ±0.30 to ±0.50: a low correlation, ±0.50 to 
0.70; a moderate correlation, ±0.70 to ±0.90; a high correlation, ±0.90 to ±1.00; a very high 
correlation. SBM: Spontaneous bowel movement; r: Spearman’s correlation coefficient.  
 
 
Abdomin
al 
symptoms 
Defecatio
n 
difficultie
s 
Reduced 
SBM 
frequency 
Incomplet
e 
evacuatio
n 
Stool 
symptoms 
Questionnaire score on 9.6 ± 16.5 31.5 ± 39.2 ± 26.6 ± 26.6 ± 
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day 5 30.0 27.8 28.0 28.7 
 
Transit time 
 
      Small intestine, r | P-
value 
0.04 | 0.85 -0.01 | 
0.97 
0.09 | 0.67 -0.17 | 
0.45 
0.02 | 0.92 
      All colon, r | P-value 0.05 | 0.81 -0.01 | 
0.98 
0.08 | 0.74 -0.16 | 
0.47 
-0.30 | 
0.18 
      Ascending colon, r | P-
value 
-0.10 | 
0.65 
-0.25 | 
0.25 
-0.16 | 
0.46 
-0.10 | 
0.69 
-0.33 | 
0.13 
      Transverse colon, r | P-
value 
0.20 | 0.37 0.22 | 0.32 0.12 | 0.60 -0.24 | 
0.27 
-0.02 | 
0.92 
      Descending colon, r | P-
value 
0.06 | 0.79 -0.01 | 
0.97 
0.24 | 0.28 -0.12 | 
0.57 
-0.26 | 
0.23 
      Rectosigmoid colon, r | 
P-value 
0.15 | 0.51 0.12 | 0.60 -0.19 | 
0.38 
-0.19 | 
0.38 
-0.03 | 
0.90 
      Total GI tract, r | P-
value 
0.07 | 0.75 0.03 | 0.90 0.08 | 0.70 -0.19 | 
0.37 
-0.29 | 
0.17 
Colonic volume      
      All colon, r | P-value 0.27 | 0.30 0.19 | 0.47 0.25 | 0.34 0.17 | 0.52 0.05 | 0.84 
      Ascending colon, r | P- 0.33 | 0.19 0.23 | 0.37 0.34 | 0.18 0.15 | 0.57 0.10 | 0.71 
ACCEPTED MANUSCRIPT
AC
C
EP
TE
D
 M
AN
U
SC
R
IP
T
 
 
value 
      Transverse colon, r | P-
value 
0.02 | 0.94 0.14 | 0.59 0.10 | 0.71 0.09 | 0.72 0.10 | 0.70 
      Descending colon, r | P-
value 
-0.09 | 
0.73 
0.08 | 0.75 0.15 | 0.56 0.07 | 0.80 -0.10 | 
0.70 
      Rectosigmoid colon, r | 
P-value 
0.18 | 0.50 0.52 | 0.94 0.16 | 0.54 0.13 | 0.61 0.12 | 0.65 
 
 
 
Discussion 
This study investigated whether correlations between subjective and objective measures of 
constipation were present, when investigated in a controlled experimental setting in which self-
reported GI symptoms were categorized into relevant groups. No correlations between the measures 
could be demonstrated.   
    Our results are in line with previous studies. Thus, a study by Cowlam et al., found no association 
between symptom severity (overall PAC-SYM score) and total GI transit time in patients with 
chronic constipation (Cowlam et al., 2008). Additionally, another study found only a poor 
correlation of subjective constipation symptoms, assessed by the Cleveland Constipation Score and 
Rome Criteria III, and colonic transit time (Knudsen, Krogh, Østergaard, & Borghammer, 2017). 
The lack of correlations between these measurements likely reflects the multifaceted and very 
subjective experience of abnormal GI function.  
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    We developed a new method to categorize GI symptoms assessed by questionnaires into relevant 
groups. This method has several advantages. Firstly, the procedure for selecting the symptoms 
included three requirements, which ensured that only the relevant symptoms were included i.e. the 
ones measurable by the objective measures and those experienced by ≥ 15 % of the participants. 
Secondly, as the symptoms were categorized based on their relation to each other (e.g. symptoms 
related to the act of defecation were placed in ‘defecation difficulties’) it was possible to analyse if 
any correlation between a specific group of related symptoms and the objective measures was 
present. Alternatively, the correlation between each of the objective measures and each single 
question of the questionnaires representing a symptom could have been investigated; however, this 
would have resulted in 400+ correlation analyses, thereby greatly increasing the risk of type I 
errors. Due to the many endpoints, any adjustment of the P-value would considerably decrease the 
chance of finding a true significant correlation.  
    As the method of categorizing symptoms into groups is new and not yet validated, results should 
be interpreted with caution. However, limitations related to the applied questionnaires and objective 
measures should also be recognized. The wordings and scales of the BFI, GSRS, and PAC-SYM 
vary, even though the questions address the same symptoms. This may potentially cause inter- and 
intra-individual variability, such as one participant might have understood one question differently 
than another participant (Olesen & Drewes, 2011). Physicians often define constipation as a 
reduction in stool frequency (typically as less than three defecations per week, as defined by the 
ROME IV criteria (Simren, Palsson, & Whitehead, 2017)) whilst patients typically think of 
constipation as a disorder combining multiple symptoms such as abdominal discomfort, straining, 
and the feeling of incomplete evacuation (Johanson & Kralstein, 2007). To give an example, in the 
BFI questionnaire, participants were asked to report their personal judgement on constipation 
severity; however, a clear definition of constipation was not provided, and thus the questionnaires 
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could be ambiguously perceived. Other limitations considers the actual study design, as we found 
that about 25% of all symptoms asked upon in the three questionnaires were rarely experienced by 
the participants, indicating that several of the questions might be irrelevant when assessing 
constipation. An explanation for this may also be the short duration of opioid treatment of merely 5 
days. Even though this was enough to induce both objectively- and subjectively-measurable GI 
changes in healthy subjects, we expect that a longer treatment period and higher doses of 
oxycodone as applied in chronic pain patients would lead to more pronounced symptoms. Thus, a 
correlation between subjective and objective measures in chronic constipation induced by e.g. 
opioids cannot be excluded. The 3D-transit system and MRI colonography applied to measure 
transit time and colonic volume respectively are well-validated methods (Haase et al., 2014; Mark 
et al., 2017; M. Nilsson et al., 2015). However, another important limitation of this study was 
missing MRI data. Thus, six participants had not expelled the capsule on day 5, which is a clear 
indication of constipation. Consequently, the colonic volumes, along with the total GI transit times, 
are likely underestimated compared to the corresponding subjective measures, which could have 
contributed to the lack of correlations.  
    It can be argued that the patient’s quality of life is more dependent on how the patient feels 
compared to any physiological aspect of the disease, suggesting that subjective measures are 
essential to capture the patient’s perspective of GI function. A study by Bell et al. found that during 
opioid treatment approximately half of the patients had normal stool frequencies (considered an 
objective measure), whilst still experiencing symptoms such as straining, bloating, and the feeling 
of incomplete bowel evacuation (Bell et al., 2009). This indicates that subjective measures are vital, 
and that even simple objective measures such as stool frequency might be an inaccurate measure of 
GI function.  
ACCEPTED MANUSCRIPT
AC
C
EP
TE
D
 M
AN
U
SC
R
IP
T
 
 
    In summary, a new method for categorizing GI symptoms of opioid treatment was presented; 
however, this was not able to show any significant correlations between subjective and objective 
measures of GI function in a controlled study of constipation. Our results, along with previous 
literature, point to that subjective and objective measures are equally important in assessment of 
constipation, and a combination of the two are recommended in clinical assessments and future 
studies of constipation and other GI diseases. 
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